The Times: “There were fewer floats but the ones that got away did very well” (28.12.15)

Motif Bio plc Second Phase 3 clinical trial in ABSSSI finishes patient treatment phase
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the last patient has completed the treatment phase in REVIVE-2, the second Phase 3 clinical trial investigating the safety